A Single-Center, 2-Part, Randomized, Double-Blind, Placebo Controlled, Single-Dose, Dose Escalation Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of AD-6626 Administered Intravenously to Normal, Healthy Volunteers (NHVs) Without Alcohol Administration in Part A and to NHVs and Subjects Heterozygous for the Aldehyde Dehydrogenase 2*1/*2 Genetic Variant With Alcohol Administration in Part B
Latest Information Update: 08 Jun 2016
Price :
$35 *
At a glance
- Drugs AD 6626 (Primary)
- Indications Alcoholic intoxication
- Focus Adverse reactions
- Sponsors ALDEA Pharmaceuticals
- 05 Jan 2015 Status changed from planning to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
- 11 Nov 2014 New trial record